[go: up one dir, main page]

MX2011005093A - Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10. - Google Patents

Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10.

Info

Publication number
MX2011005093A
MX2011005093A MX2011005093A MX2011005093A MX2011005093A MX 2011005093 A MX2011005093 A MX 2011005093A MX 2011005093 A MX2011005093 A MX 2011005093A MX 2011005093 A MX2011005093 A MX 2011005093A MX 2011005093 A MX2011005093 A MX 2011005093A
Authority
MX
Mexico
Prior art keywords
pyridine
phosphodiesterase
inhibitors
pyrimidine derivatives
compounds
Prior art date
Application number
MX2011005093A
Other languages
English (en)
Inventor
Ning Chen
Kelvin Sham
Holger Monenschein
Frenel Fils Demorin
Jennifer R Allen
Essa Hu
Roxanne Kunz
Paul E Harrington
Andreas Reichelt
James R Falsey
Frank Chavez Jr
Kaustav Biswas
Mike Frohn
Daniel B Horne
Matthew R Kaller
Tom Nguyen
Alex Pickrell
Shannon Rumfelt
Rob Rzasa
Guomin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2011005093A publication Critical patent/MX2011005093A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de piridina y pirimidina, y composiciones que los contienen, y proceso para preparar tales compuestos. También se proporcionan en la presente métodos para tratar trastornos o enfermedades tratables por inhibición de PDE10, tales como obesidad, diabetes no dependiente de la insulina, esquizofrenia, trastorno bipolar, trastorno obsesivo compulsivo, y similares.
MX2011005093A 2008-11-14 2009-11-16 Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10. MX2011005093A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11459508P 2008-11-14 2008-11-14
US16621509P 2009-04-02 2009-04-02
PCT/US2009/064643 WO2010057126A1 (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors

Publications (1)

Publication Number Publication Date
MX2011005093A true MX2011005093A (es) 2011-09-27

Family

ID=41557471

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005093A MX2011005093A (es) 2008-11-14 2009-11-16 Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10.

Country Status (17)

Country Link
US (2) US8318718B2 (es)
EP (1) EP2364306B1 (es)
JP (1) JP2012508777A (es)
KR (1) KR20110086603A (es)
AR (1) AR074343A1 (es)
AU (1) AU2009313773B2 (es)
BR (1) BRPI0921598A2 (es)
CA (1) CA2742833C (es)
CR (1) CR20110279A (es)
EA (1) EA201100749A1 (es)
ES (1) ES2413808T3 (es)
IL (1) IL212670A0 (es)
MA (1) MA32891B1 (es)
MX (1) MX2011005093A (es)
TN (1) TN2011000220A1 (es)
TW (1) TW201030001A (es)
WO (1) WO2010057126A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744383C (en) 2008-11-21 2017-04-25 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
SG173175A1 (en) 2009-02-05 2011-09-29 Takeda Pharmaceutical Pyridazinone compounds
NZ605889A (en) 2010-06-24 2014-10-31 Takeda Pharmaceutical Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8883788B2 (en) 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
CN103619841B (zh) 2011-01-11 2017-03-29 桑诺维恩药品公司 杂芳基化合物及其使用方法
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
JP5973990B2 (ja) * 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
KR20190011343A (ko) 2011-06-10 2019-02-01 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
TWI570122B (zh) 2011-06-22 2017-02-11 武田藥品工業股份有限公司 稠合雜環化合物之結晶
BR112013033316A2 (pt) 2011-06-24 2017-01-31 Amgen Inc antagonista de trpm8 e seu uso em tratamentos
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
ME02419B (me) * 2011-08-25 2016-09-20 Merck Sharp & Dohme Inhibitori pirimidina pde10
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
JP2016531870A (ja) 2013-09-27 2016-10-13 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
JP6785217B2 (ja) * 2014-07-31 2020-11-18 インスティチュート パスツール コリア ２−アミノ−ベンゾイミダゾール誘導体ならびにこれらの５−リポキシゲナーゼおよび／またはプロスタグランジンｅシンターゼ阻害剤としての使用
RU2760373C2 (ru) 2015-09-18 2021-11-24 Какен Фармасьютикал Ко., Лтд. Биарильное производное и содержащее его лекарственное средство
CN110563664A (zh) * 2019-07-23 2019-12-13 上海合全药物研发有限公司 外消旋体(4as,7s,7as)-叔丁基-7-羟基六氢环戊二烯[b][1,4]噁嗪-4(4ah)-甲酸基酯制法
BR112023020381A2 (pt) * 2021-05-12 2023-11-21 Boehringer Ingelheim Int Derivados de piridina com substituintes cíclicos ligados por c como inibidores de cgas
JP2024519306A (ja) * 2021-05-12 2024-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ｃＧＡＳ阻害薬としてのＮ結合環状置換基を有するピリジン誘導体
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
DE602004013314T2 (de) 2003-04-04 2008-08-07 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6-tetrahydropyridin-derivate als serotonin-wiederaufnahme-hemmer
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
WO2007016228A2 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
JP2011524917A (ja) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用

Also Published As

Publication number Publication date
TN2011000220A1 (en) 2012-12-17
CA2742833C (en) 2013-12-31
AU2009313773B2 (en) 2013-03-21
BRPI0921598A2 (pt) 2016-02-10
CR20110279A (es) 2011-09-22
US8759532B2 (en) 2014-06-24
KR20110086603A (ko) 2011-07-28
JP2012508777A (ja) 2012-04-12
CA2742833A1 (en) 2010-05-20
EP2364306B1 (en) 2013-04-24
TW201030001A (en) 2010-08-16
WO2010057126A1 (en) 2010-05-20
US20130079325A1 (en) 2013-03-28
EA201100749A1 (ru) 2011-10-31
ES2413808T3 (es) 2013-07-17
MA32891B1 (fr) 2011-12-01
US8318718B2 (en) 2012-11-27
EP2364306A1 (en) 2011-09-14
AU2009313773A1 (en) 2010-05-20
US20100125062A1 (en) 2010-05-20
AR074343A1 (es) 2011-01-12
IL212670A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
TN2011000220A1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
TN2012000530A1 (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
MX2008011258A (es) Derivados de quinazolina como inhibidores de fosfodiesterasa 10.
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
MX2008010953A (es) Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
MX2010007392A (es) Antagonistas de trpa1.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MY151246A (en) Benzofuranyl derivatives
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
ZA201000079B (en) Organic compounds
WO2009108383A3 (en) Substituted xanthine derivatives
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
WO2009151598A8 (en) Diazacarbazoles and methods of use
MX2010007391A (es) Antagonistas de trpa1.
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX2008011175A (es) Inhibidores de fosfodiesterasa 10.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives
GB2469980A (en) Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof

Legal Events

Date Code Title Description
FG Grant or registration